This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colman, R. W. Articles by Idell, S. Search for Related Content PubMed PubMed Citation Articles by Colman, R. W. Articles by Idell, S.

American Journal of Pathology, Vol 130, 418-426, Copyright © 1988 by American Society for Investigative Pathology

REGULAR ARTICLES

Recombinant alpha 1-antitrypsin Pittsburgh attenuates experimental gram- negative septicemia

RW Colman, DN Flores, RA De La Cadena, CF Scott, L Cousens, PJ Barr, IB Hoffman, F Kueppers, D Fisher and S Idell
Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA 19140.

Alpha 1-antitrypsin-Pittsburgh (AT-P), a naturally occurring lethal mutation (358Met----Arg), has been genetically engineered (rAT-P). The protein has been shown to be a potent active site-directed inhibitor of thrombin and the contact enzymes Factor XIIf, Factor XIa, and kallikrein. Because activation of the contact system is known to occur in gram-negative septicemia, the authors have hypothesized that the administration of rAT-P might modulate the course of this syndrome. Yorkshire piglets anesthetized with pentobarbital and infused with viable Pseudomonas aeruginosa (2 X 10(8) CFU) were untreated (Group I) or treated with rAT-P (Group II) and studied in a 6-hour protocol. Coagulation studies revealed that rAT-P significantly inhibited the rapid decrease in the functional concentrations of Antithrombin III, Factor XI, and fibrinogen. In addition, rAT-P markedly reduced the serum levels of fibrinogen degradation products. Survival in Group II was significantly increased during 2-5 hours but not at 6 hours when the functional levels of rAT-P in plasma were the lowest. These results indicate that this recombinant inhibitor, even at low concentrations, affords protection in experimental gram-negative septicemia.

This article has been cited by other articles:

				T. Sulikowski, B. A. Bauer, and P. A. Patston {alpha}1-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1 Protein Sci., September 1, 2002; 11(9): 2230 - 2236. [Abstract] [Full Text] [PDF]

				A Stadnicki, R B Sartor, R Janardham, I Stadnicka, A A Adam, C Blais Jr, and R W Colman Kallikrein-kininogen system activation and bradykinin (B2) receptors in indomethacin induced enterocolitis in genetically susceptible Lewis rats Gut, September 1, 1998; 43(3): 365 - 374. [Abstract] [Full Text] [PDF]